XavTrap®

XavTrap is a recombinant platform technology using yeast cell fragments to rapidly express single-chain variable fragment (scFV), nanobodies or peptides for diagnostic applications. This platform technology can be rapidly made to target a specific disease (Disease X), including seasonal mutations of influenzas and coronavirus. Xing XavTrap® platform produces lead candidates 66% faster than cutting edge mammalian antibody pipelines, which XING has validated as part of the NIH-RADx Program*.